Table 2.

Usage of post-discharge cardiovascular prescription medication in hospital surviving RA patients and matched controls after myocardial infarction

	RA	Matched controls
	n = 1366	n = 6995	OR (95% CI)	P-value
ADP-inhibitor	827 (60.5%)	4288 (61.3%)	0.96 (0.85, 1.09)	0.521
Anticoagulant	205 (15.0%)	1067 (15.3%)	1.00 (0.84, 1.18)	0.957
Antidiabetic	231 (16.9%)	1260 (18.0%)	0.91 (0.78, 1.07)	0.251
Insulin	111 (8.1%)	587 (8.4%)	0.98 (0.79, 1.22)	0.832
Non-insulin	151 (11.1%)	873 (12.5%)	0.84 (0.70, 1.02)	0.071
ACEi or ARB	855 (62.6%)	4561 (65.2%)	0.91 (0.80, 1.03)	0.117
Aldosterone antagonist	59 (4.3%)	277 (4.0%)	1.10 (0.82, 1.48)	0.509
Antiarrhythmic	11 (0.8%)	90 (1.3%)	0.65 (.0.34, 1.23)	0.187
Beta-blocker	1147 (84.0%)	5764 (82.4%)	1.11 (0.94, 1.30)	0.217
Ca-blocker	253 (18.5%)	1310 (18.7%)	0.97 (0.84, 1.14)	0.739
Digitalis	62 (4.5%)	307 (4.4%)	1.04 (0.78, 1.38)	0.788
Diuretic	634 (46.4%)	3176 (45.4%)	1.06 (0.94, 1.19)	0.351
Ezetimibe	28 (2.1%)	166 (2.4%)	0.86 (0.57, 1.30)	0.463
Nitrate	960 (70.3%)	4863 (69.5%)	1.03 (0.91, 1.17)	0.651
Statin	998 (73.1%)	5410 (77.3%)	0.79 (0.69, 0.91)	0.001
Intensity of statin therapy				0.281
Low	49 (4.9%)	311 (5.8%)
Moderate	804 (80.6%)	4272 (79.0%)
High	145 (14.5%)	827 (15.3%)

ACEi: angiotensin-converting-enzyme inhibitor; ADP: adenosine diphosphate; ARB: angiotensin receptor blocker; OR: odds ratio.